Health Condition 1: K642- Third degree hemorrhoids
Conditions
Interventions
Intervention1: Aesculus Hippocastanum Mother Tincture: Intervention Group A
Patients will receive Aesculus hippocastanum mother tincture, 10 15 drops in half a cup of water, twice daily for 6 8 weeks,
Sponsors
Dr Aparna Ravsaheb Birari
Eligibility
Inclusion criteria
Inclusion criteria: Individuals who have been clinically confirmed to be suffering from haemorrhoids whether internal or external falling within Grades I to III will be considered for the study Participants between the ages of 18 and 60 of any gender will be eligible Only those who agree to undergo HOMOEOPATHY treatment and are ready to follow up as advised will be included The study will involve individuals showing common symptoms such as rectal bleeding, pain during defecation, itching, or prolapse Patients not currently under any form of alternative treatment or conventional medication for haemorrhoids will be selected Patient of both sexes and all socio-economic class in 45-65 AGE group Cases showing sign and symptom of haemorrhoid and other ano rectal disease or cases diagnosed as haemorrhoid & anal fissure are to be considered
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with Grade IV haemorrhoids, or those advised to undergo surgical procedures, will not be taken into the study. 2.People suffering from other anorectal disorders like fistulas, or suspected malignancies will be excluded. 3.Individuals with significant health issues such as poorly managed diabetes, severe liver problems, or high blood pressure will not be considered. 4.Pregnancy or breasfeding women will be excluded to maintain both maternal and fetal safety during the study period. 5.Anyone unwilling to participate, or unable to commit to the study guidelines and follow-ups, will not be included. 6 Cases with diagnosed anal fistula, rectal cancer, or anorectal abscess. 7.Patients with systemic illnesses that may interfere with the treatment response (example, uncontrolled diabetes, HIV). 8. Individuals currently on long-term allopathic or corticosteroid treatment for the same condition. 9.Immunocompromised patients will be excluded from the study . 10.Patients with bleeding diathesis are excluded .(example-low platelets counts , blood clotting disorders )
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes are the reduction in pain intensity as measured by the Visual Analogue Scale and the improvement in the frequency and severity of rectal bleeding.Timepoint: Duration of study is 18 months These outcomes will be assessed at baseline Day 0 at the end of 4 weeks, and at the end of 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes include the assessment of changes in rectal swelling discharge from anus And bowel habitsTimepoint: General well being will be assessed qualitatively at each followup visit And final assessment will be done at the end of the study | — |
Countries
India
Contacts
Public ContactDr Smita Hiwrale
Guru Mishri Homoeopathic Medical College and Hospital, Shelgaon, Jalna
Outcome results
None listed